News

EoE expert Dr. Marc Rothenberg says it's a relief to know that the FDA has finally approved a drug for EoE.

Oral doses of 3 Janus kinase inhibitors show the therapies out-performed placebo in all outcomes measured in patients with moderate-to-severe AD.

Despite most adverse events of special interest being deemed mild to moderately severe in nature, these types of events have been increasingly reported in real-world practice.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 28, 2022.

Despite this, close gynecological monitoring of pregnant women with PR was still recommended.

RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.

Gina Poe, PhD, discusses the potential role of beta blockers in treating psychiatric illness-related sleep, as well as the specific benefit of melatonin.

NIDA research director Carlos Blanco-Jerez, MD, PhD, reviews how stigma, language barriers and digital health create disparate outcomes in mentally-ill Hispanic patients.

Lois Choi-Kain, MD, MEd, discusses her field's interest in improving the modern diagnosis and evidenced-based treatment of personality disorders.

The UCLA-based investigator discusses the unique impact of PTSD on patients' sleep stages, and how they can limit their insomnia.

Look back on Rheumatology Network's Congress of Clinical Rheumatology (CCR) East's conference coverage.

With limitations on fidaxomicin at their facility, a hospital looked at vancomycin usage to determine if they needed to align with the new IDSA/SHEA CDI treatment guideline.

Keratosis pilaris has often been associated with AD and filaggrin loss-of-function mutations, the latter of which are frequent in Europe with an approximate prevalence of 7%

At DDW 2022, Dr. Sands highlights the positive findings from the LUCENT-1 study on the efficacy and safety of mirikizumab.

Patients treated with ustekinumab are not at an increased risk of malignancies.

COVID-19 has raised additional concerns for rheumatologists, especially regarding health care for patients with rheumatic diseases.

Investigators led by Dr. Bowie deemed it necessary to establish “transparent classification” of topical corticosteroids in the pursuit of stronger and more reliable dermatologic outcomes and treatments.

Treating the disease could reduce the risk of patient distress.

The director of NIDA discusses the interplay of substance use disorder and pain in patients, as well as means to assure patients are receiving evidenced-based treatment.

Lois Choi-Kain, MD, MEd, discusses the unique presentations of disease and burdens of care that impact younger patients with BPD.

The modern psychiatrist may play many roles, including as a mentor and a facilitator to social-based support.

Though patients with undifferentiated pruritus had higher serum LDH levels, these levels were not associated with an increased risk of hematologic cancer.

Investigators conducted a meta-analysis to determine the association between psoriasis and an eventual psoriatic arthritis diagnosis.

Prior to this new data, only 2 studies had evaluated the association between psoriasis and NAFLD in the US.

Investigators suggested that the large number of systemic therapies used when treating HS in these patients indicated referral delays or difficulties in obtaining disease control in those with moderate to severe HS.

Anne Winkler, MD, discusses the importance of patient-reported outcome measures when treating her patients with lupus.

There are several live microbiota therapeutics in development, including RBX2660.

Data show the safety profile of Ustekinumab in long-term IBD pooled safety dataset was found favorable among bionaive patients.

The treatment has previously been approved by the FDA for the treatment of ulcerative colitis.

A discussion on the role of PLSec-AFP for HCC risk stratification in patients with cirrhosis and future screening implementations.